Join

Compare · ABSI vs NOTV

ABSI vs NOTV

Side-by-side comparison of Absci Corporation (ABSI) and Inotiv Inc. (NOTV): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ABSI and NOTV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
  • ABSI is the larger of the two at $1.65B, about 592.9x NOTV ($2.8M).
  • ABSI has hit the wire 6 times in the past 4 weeks while NOTV has been quiet.
  • ABSI has more recent analyst coverage (21 ratings vs 9 for NOTV).
MetricABSINOTV
Company
Absci Corporation
Inotiv Inc.
Price
-
-
Market cap
$1.65B
$2.8M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Commercial Physical & Biological Resarch
Exchange
NASDAQ
NASDAQ
IPO
2021
News (4w)
6
0
Recent ratings
21
9
ABSI

Absci Corporation

Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.

NOTV

Inotiv Inc.

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Latest ABSI

Latest NOTV